Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)
Conditions
Interventions
TAK-771
Locations
9
Japan
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Hospital of University of Occupational and Environmental Health
Kitakyushu, Fukuoka, Japan
Gifu University Hospital
Gifu, Gifu, Japan
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Kanagawa Children's Medical Center
Yokohama, Kanagawa, Japan
Start Date
September 13, 2022
Primary Completion Date
October 31, 2025
Completion Date
October 31, 2025
Last Updated
November 17, 2025
NCT05755035
NCT03277313
NCT01218438
NCT00814320
NCT01175213
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions